COVID-19 Vaccination Status and Hesitancy among Breast Cancer Patients after Two Years of Pandemic: A Cross-Sectional Survey.
Vaccines (Basel)
; 10(9)2022 Sep 15.
Article
in English
| MEDLINE | ID: covidwho-2044007
ABSTRACT
BACKGROUND:
Patients with cancer show greater susceptibility and vulnerability to severe acute respiratory syndrome coronavirus 2 infection. However, data on the vaccination status among patients with breast cancer and any structured analysis of the factors influencing patients' decisions regarding vaccines are lacking.METHODS:
This cross-sectional study on patients with breast cancer in China was conducted from 1 June 2022, to 17 June 2022. Every participant completed an online questionnaire about their vaccination status and any adverse reactions, and a scale based on the Health Belief Model (HBM) to assess the vaccination status of respondents and their willingness to receive following doses or boosters.RESULTS:
Among the 1132 participants, 55.2% had received a COVID-19 vaccine. The incidence of adverse events per dose was around 40%. Vaccine hesitancy of 61.9% was observed among patients who had not fully received three doses of vaccine or boosters. The only variable found to be associated with vaccine hesitancy was time since diagnosis (p < 0.05). In the HBM scale, vaccine hesitancy was closely related to a low level of perceived susceptibility, a low level of perceived benefit, a high level of perceived barriers and a low level of agreement with doctors' advice.CONCLUSIONS:
For patients with breast cancer, perceived susceptibility, benefits and barriers should be prioritized, and the advice from authoritative doctors is a vital cue to action.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
/
Qualitative research
/
Randomized controlled trials
Topics:
Vaccines
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Vaccines10091530
Similar
MEDLINE
...
LILACS
LIS